docetaxel anhydrous has been researched along with Leanness in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q | 1 |
| Barrett, SV; Glasspool, RM; Hay, A; Kaye, SB; Paul, J; Vasey, PA | 1 |
1 trial(s) available for docetaxel anhydrous and Leanness
| Article | Year |
|---|---|
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Middle Aged; Obesity; Ovarian Neoplasms; Overweight; Paclitaxel; Survival Analysis; Taxoids; Thinness | 2008 |
1 other study(ies) available for docetaxel anhydrous and Leanness
| Article | Year |
|---|---|
Myelosuppression by chemotherapy in obese patients with gynecological cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ideal Body Weight; Japan; Middle Aged; Obesity; Paclitaxel; Retrospective Studies; Taxoids; Thinness; Young Adult | 2016 |